Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:CNTX NASDAQ:IGMS NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.94+12.2%$0.76$0.51▼$1.37$90.66M0.35318,959 shs745,140 shsCNTXContext Therapeutics$0.87+2.6%$0.80$0.49▼$2.59$78.04M1.91190,660 shs83,899 shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/ALSTALisata Therapeutics$2.33+1.1%$2.51$1.87▼$4.20$20.37M1.0130,845 shs9,022 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+4.58%+5.12%+3.30%+27.43%-32.27%CNTXContext Therapeutics+4.43%+0.27%+7.82%+50.40%-59.24%IGMSIGM Biosciences0.00%0.00%0.00%+8.55%-91.98%LSTALisata Therapeutics+8.49%+4.55%-9.09%-8.15%-20.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.94+12.2%$0.76$0.51▼$1.37$90.66M0.35318,959 shs745,140 shsCNTXContext Therapeutics$0.87+2.6%$0.80$0.49▼$2.59$78.04M1.91190,660 shs83,899 shsIGMSIGM Biosciences$1.27$1.28$0.92▼$22.50$76.57M0.6480,746 shsN/ALSTALisata Therapeutics$2.33+1.1%$2.51$1.87▼$4.20$20.37M1.0130,845 shs9,022 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+4.58%+5.12%+3.30%+27.43%-32.27%CNTXContext Therapeutics+4.43%+0.27%+7.82%+50.40%-59.24%IGMSIGM Biosciences0.00%0.00%0.00%+8.55%-91.98%LSTALisata Therapeutics+8.49%+4.55%-9.09%-8.15%-20.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 2.33Hold$2.38152.12% UpsideCNTXContext Therapeutics 3.17Buy$5.25503.45% UpsideIGMSIGM Biosciences 1.89Reduce$4.89284.95% UpsideLSTALisata Therapeutics 3.00Buy$23.50910.75% UpsideCurrent Analyst Ratings BreakdownLatest LSTA, ASRT, IGMS, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ASRTAssertioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/21/2025LSTALisata TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/12/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.50 ➝ $3.008/7/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.008/7/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $32.006/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.50 ➝ $4.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.73$0.06 per share16.36$1.27 per share0.74CNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/AIGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76LSTALisata Therapeutics$1M20.37N/AN/A$3.49 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.45N/A31.40N/A-36.97%-38.19%-15.45%11/10/2025 (Estimated)CNTXContext Therapeutics-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)IGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)LSTALisata Therapeutics-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)Latest LSTA, ASRT, IGMS, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ASRTAssertio-$0.10-$0.17-$0.07-$0.17$27.86 million$29.22 million8/7/2025Q2 2025LSTALisata Therapeutics-$0.65-$0.54+$0.11-$0.54N/A$0.07 million8/6/2025Q2 2025CNTXContext Therapeutics-$0.06-$0.09-$0.03-$0.09N/AN/A7/31/2025Q2 2025IGMSIGM Biosciences-$0.30$1.58+$1.88$1.58$3.20 million$143.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.421.591.34CNTXContext TherapeuticsN/A19.0919.09IGMSIGM BiosciencesN/A17.6617.66LSTALisata TherapeuticsN/A5.775.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%CNTXContext Therapeutics14.03%IGMSIGM Biosciences42.79%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%CNTXContext Therapeutics3.04%IGMSIGM Biosciences57.00%LSTALisata Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2096.24 million92.39 millionOptionableCNTXContext Therapeutics789.70 million86.98 millionNot OptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableLSTALisata Therapeutics308.76 million7.96 millionNot OptionableLSTA, ASRT, IGMS, and CNTX HeadlinesRecent News About These CompaniesLisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comLisata extends cash runway into Q4 2026 while advancing certepetide development milestonesAugust 9, 2025 | msn.comLisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comLisata Therapeutics advances lead cancer drug, expects key trial results by year-endAugust 7, 2025 | proactiveinvestors.comLisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7, 2025 | globenewswire.comLisata Therapeutics Q2 2025 Earnings PreviewAugust 7, 2025 | msn.comLisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025July 31, 2025 | globenewswire.comLisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary resultsJuly 17, 2025 | proactiveinvestors.comLisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data UpdateJuly 17, 2025 | globenewswire.comLisata Therapeutics, Inc.: Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | finanznachrichten.deLisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | finance.yahoo.comLisata Therapeutics expands IP with key patent covering certepetide's chemical structure and usesJuly 15, 2025 | proactiveinvestors.comLisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | globenewswire.comLisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMIJuly 12, 2025 | proactiveinvestors.comLisata Therapeutics, Inc. (LSTA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comLisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancerJune 26, 2025 | proactiveinvestors.comLisata and GATC to use AI for new opioid use disorder drugJune 18, 2025 | thepharmaletter.comTLisata Therapeutics to lead development of opioid use disorder drug under expanded allianceJune 17, 2025 | proactiveinvestors.comLisata Therapeutics, Inc.: Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSTA, ASRT, IGMS, and CNTX Company DescriptionsAssertio NASDAQ:ASRT$0.94 +0.10 (+12.16%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Context Therapeutics NASDAQ:CNTX$0.87 +0.02 (+2.62%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.IGM Biosciences NASDAQ:IGMSIGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Lisata Therapeutics NASDAQ:LSTA$2.33 +0.03 (+1.09%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
